Optimizing Screening Methods for Nasopharyngeal Carcinoma Using Plasma EBV DNA and P85 Antibodies Compared to Standard Antibody Tests in High-Risk Areas

What this Trial Is About

Researchers are evaluating new screening methods for nasopharyngeal carcinoma NPC in people at high risk, focusing on Epstein-Barr virus EBV associated biomarkers. This study compares plasma EBV DNA testing and BNLF2b total antibodies P85-Ab with the current standard two-antibody method VCA-IgA and EBNA1-IgA. The goal is to find the best initial screening approach that improves detection sensitivity while keeping accuracy high, which could reduce the need for invasive procedures and lower medical costs. Participants between 30 and 69 years old will have blood, nasopharyngeal swab, and saliva samples collected for testing various EBV biomarkers. The study will explore both a two-step screening methodstarting with antibody tests followed by plasma EBV DNA testing for positive casesand a single-step method where all tests are done simultaneously. Those identified as high-risk will undergo endoscopic examinations, with or without biopsy, to confirm findings. Participants will be followed and tested at the start, then again at 3 years and 10 years to measure the sensitivity, specificity, predictive values, and early diagnosis rates of each screening method. Researchers will also monitor death rates related to NPC and all causes. The study is designed to track these outcomes over a long period while ensuring participants can cooperate with ongoing follow-up to assess the screening strategies effectiveness and efficiency.

Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas